Radiologic-Molecular Correlation in DMG Recurrence

Diffuse midline gliomas (DMGs) are highly aggressive brain tumors most often seen in children between the ages of 6.5-10 years old and have a survival time of less than one year after diagnosis. Magnetic resonance imaging (MRI) is the standard practice for diagnosing DMGs and monitoring their response to therapy. Because of this, nearly every child diagnosed with a DMG has an MRI of their tumor, and researchers are trying to investigate other ways to use these images to classify patients based on risk without needing tumor biopsy. We have found that the level of contrast-enhancing tumor tissue, which is associated with necrosis, is higher, and stays higher after treatment in those with a poor prognosis. To bring this finding to use in DMG treatment, we must also investigate the genomic profiles of the contrast-enhancing tissue. Patient data provided by the CBTN will be integral to this study as, CBTN has the largest dataset of genetic data for patients with DMG. If successful, this will help clarify tumor MRI findings that can better define patients at high-risk for recurrence, leading to improved management for children with DMGs.